Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
A Mayo Clinic study found postmenopausal women using hormone therapy alongside tirzepatide (a GLP-1/GIP dual agonist) experienced notably greater weight loss compared with those using tirzepatide without HRT
4.0Trustpilot(6,500)Verified Aug 1, 2026SourceVisit siteNot published price hidden until intake Tirzepatide injectable Ro Body membership is $39 the first month, then $149/mo ($74/mo equivalent if you prepay annually)
It also benchmarks progress against clinical-trial data and anonymous peers
For the first time, a clinically validated, DCGI-approved, affordable GLP-1 therapy is within reach for millions of Indians who need it
Reduced insulin sensitivity (IS) in women with obesity contributes to hyperinsulinemia and may lead to PCOS (3)
US$ 23.44
US$ 22.88
US$ 23.10
